Raltegravir in pregnancy: A case series presentation

International Journal of STD and AIDS

Volumn 22, Issue 6, 2011, Pages 358-360

  Taylor, N ^a   Touzeau, V ^b   Geit, M ^c   Gisinger, M ^d   Egle, A ^a   Greil, R ^a   Rieger, A ^b   Zangerle, R ^d  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Division of Infectious Diseases   (Austria)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antiretroviral therapy; HIV; Mother to child transmission; Pregnancy; Raltegravir; Women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR; ENFUVIRTIDE; LAMIVUDINE; RALTEGRAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CESAREAN SECTION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLAGIOCEPHALY; PREGNANCY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRROLIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79959516091     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.010469     Document Type: Article

References (10)

1. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22:973-81
2. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008;22:289-99
3. Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 2010;15:677-80
4. McKeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010;24:2416-8
5. Pinnetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010;65:2050-52
6. Antiretroviral Pregnancy Registry Steering Committee, editor. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2009. 2009
7. Clarren SK. Plagiocephaly and torticollis: etiology, natural history, and helmet treatment. J Pediatr 1981;98:92-5
8. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010;50:605-12
9. Read P, Khan P, Mandalia S, et al. When should HAART be initiated in pregnancy to achieve an undetectable viral load? Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, 2010, San Francisco, USA, Abstract 896
10. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with motherto-child transmission of HIV-1 despite a maternal viral load,500 copies/mL at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1),500 copies/mL at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010;50:585-96